Given that in human melanomas at least 60% of tumours express BRAF mutations100, we next explored whether the efficiency of the opposite targeting of p110δ PI3K and RhoA in preventing melanoma progression is altered when BRAF is mutated. This evidence concerns the gene RHOA and melanoma.